Pharmaceuticals
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-19 09:00
1285
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27....
2026-08-18 22:15
2143
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a late c...
2026-08-17 20:00
3762
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
* Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages * Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is ...
2026-08-17 12:34
1998
New Study Confirms Capsugel® Enprotect® Capsules Deliver Robust Gastric Integrity Under Both Fasted and Fed Conditions
SEOUL, South Korea, Aug. 14, 2026 /PRNewswire/ -- Enteric capsules are widely used to protect acid-sensitive compounds and to delay drug release until intestinal entry. However, evidence supporting their gastric integrity under physiologically relevant fed-state conditions remains limited, as mos...
2026-08-17 11:45
2371
IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
NANJING, China and SINGAPORE, Aug. 14, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio) today announced the completion of its acquisition of MediSix Therapeutics ("MediSix"), a Singapore-based immune cell engineering and cell therapy company. This acquisition marks a step in IASO Bio's global...
2026-08-14 20:20
6859
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
SHANGHAI, Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected infant patients, including the ones in pediat...
2026-08-14 18:18
2559
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- Innorna, a clinical-stage biotech company advancing RNA medicines, today announced that it has been nominated for the2026 Prix Galien USA Best Startup Award. Innorna was shortlisted in the Best Startup c...
2026-08-13 22:00
2916
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been app...
2026-08-13 09:00
3724
Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026
Following REJURAN®'s TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. GANGNEUNG, South Korea, Aug. 13, 2026 /PRNewswire/ -- PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesth...
2026-08-13 08:00
4281
Osara Health Marks 10 Years with Global Call to Make Cancer Support Beyond Treatment Standard
Launched to mark the company's 10th anniversary, Osara Health's Global Cancer Support Declaration has already secured signatures from healthcare professionals worldwide. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Osara Health, a global digital health company focused on the human experience of cance...
2026-08-12 23:17
3093
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....
2026-08-12 17:38
2974
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co....
2026-08-12 17:10
2998
Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging
VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging MILAN, Aug. 11, 2026 /PRNewswire/ -- Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to ...
2026-08-11 20:00
1877
Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond
* PDRN Derma cream, serum, and mask lineup positions premium K-dermocosmetics based on patented ingredients for Southeast Asian market expansion CHUNCHEON, South Korea, Aug. 11, 2026 /PRNewswire/ -- K-Medichem Co., Ltd. (K-Medichem), a Korean biotech company built on university research, is acc...
2026-08-11 19:17
3064
Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add adva...
2026-08-11 18:00
2262
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...
2026-08-10 19:00
4191
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...
2026-08-10 17:36
2917
Alebund's AP301 NDA Accepted for Review by China's NMPA
SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...
2026-08-07 18:40
2954
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...
2026-08-06 18:46
3601
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 320 media titles]
2026-08-28 09:01Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 312 media titles]
2026-09-03 23:53
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00